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Purpose: Controversy exists regarding the use of intravitreal dexamethasone (IVD) as an 
anti-inﬂ  ammatory adjunct to intravitreal antibiotics in patients with acute endophthalmitis fol-
lowing cataract surgery. The purpose of this project was to evaluate our experience regarding 
the effect of adjunctive IVD use on visual outcomes in such patients.
Design: Retrospective, comparative case series.
Methods: Study population: Patients treated for acute endophthalmitis following cataract 
surgery from 1995–2004. Intervention: In addition to standard intravitreal antibiotic treatment, 
some patients also received a single adjunctive injection of IVD. Primary outcome measures: 
Median visual acuity at last follow-up and percentage of patients achieving a 3-line improve-
ment in visual acuity. Secondary outcome measures: Inﬂ  ammatory index scoring, including 
amount of cell and ﬂ  are, height of hypopyon, and presence of ﬁ  brin as a function of time after 
treatment.
Results: Twenty-six eyes were treated with and 38 eyes without adjunctive IVD. Median 
presenting visual acuity was Hand Motion in both groups. Median visual acuity at last follow-
up measured 20/40 in the IVD group and 20/50 in the No-IVD group (p = 0.75). Seventy-three 
percent of patients in the IVD group and 82% of patients in the No-IVD group achieved 
a 3-line improvement in visual acuity (p = 0.42). No signiﬁ  cant difference was detected 
between the IVD and No-IVD groups for any of the three measures of inﬂ  ammation.
Conclusion: The use of IVD did not signiﬁ  cantly improve the ﬁ  nal median visual acuity, 
the chance of achieving a 3-line improvement in visual acuity, or the amount of intraocular 
inﬂ  ammation. Based on these ﬁ  ndings, and the possible detrimental effect of IVD on visual 
outcomes previously reported in the literature, the use of IVD does not appear to be warranted 
as a routine adjunctive treatment in postoperative endophthalmitis.
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Introduction
The Endophthalmitis Vitrectomy Study (EVS) helped provide treatment guidelines 
(EVSG 1995) for acute postoperative endophthalmitis, a potentially devastating 
complication of intraocular surgery. Although the use of intravitreal dexamethasone 
(IVD) was not studied in the EVS, this adjunctive treatment has gained popularity as 
a means to potentially decrease intraocular inﬂ  ammation and thereby improve visual 
outcomes. In the 2004 Preference and Trends Survey of practicing retina specialists 
conducted by the American Society of Retina Specialists, 43% of respondents said 
that they routinely use intravitreal steroids as an adjunct to intravitreal antibiotics in 
the treatment of endophthalmitis patients (Pollack 2006).
Despite the intuitive appeal of decreasing intraocular inﬂ  ammation, the clinical 
beneﬁ  t of this practice has yet to be validated in the literature. To date, only three 
studies speciﬁ  cally examine the effect of this adjunctive treatment on visual acuity Clinical Ophthalmology 2008:2(1) 140
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outcomes, and they present conﬂ  icting results (Das et al 
1999; Shah et al 2000; Gan et al 2005a). One retrospective 
analysis reported a detrimental effect of adjunctive IVD, 
with patients receiving adjunctive IVD signiﬁ  cantly less 
likely to obtain a 3-line improvement in visual acuity than 
patients receiving intravitreal antibiotics only (Shah et al 
2000). One prospective study found that visual outcomes 
were similar in patients treated with or without adjunctive 
IVD, however, certain subsets of IVD-treated patients did 
have a more rapid resolution of their intraocular inﬂ  ammation 
(Das et al 1999). The third study, also prospective in nature, 
suggested a trend towards improved vision with IVD, though 
statistical signiﬁ  cance was not achieved (Gan et al 2005a). 
In animal models of endophthalmitis, the beneﬁ  t of IVD has 
varied. Some investigators have reported that IVD appears 
to decrease intraocular inﬂ  ammation and perhaps attenuate 
retinal necrosis on a histopathologic basis (Maxwell et al 
1991; Park et al 1995; Smith et al 1997; Yoshizumu et al 
1998; Liu et al 2000; Yildrim et al 2002). Others have 
reported no overall beneﬁ  t (Jett et al 1995; Kim et al 1996; 
Pollack et al 2004) and perhaps even harmful effects 
(Meredith et al 1996). Intravitreal dexamethasone may also 
affect the concentration of intravitreal vancomycin, though 
this too is unclear, with one study showing lower vancomycin 
concentrations (Smith et al 1991) and another study showing 
a signiﬁ  cantly increased half-life of intravitreal vancomycin 
in the presence of IVD (Park et al 1999). A recent human 
study found that IVD did not decrease the intravitreal 
vancomycin concentration (Gan et al 2005b).
With the recent suggestion that endophthalmitis rates 
have been increasing (West et al 2005), and the equivocal and 
conﬂ  icting animal and human clinical studies to guide us in 
our use of adjunctive IVD, we sought to review our experi-
ence with the use of IVD in improving visual outcomes and 
decreasing inﬂ  ammation in patients with acute, post-cataract 
endophthalmitis.
Methods
Charts of all consecutive patients diagnosed and treated by 
the Retina Service at the University of Michigan’s Kellogg 
Eye Center for acute postoperative endophthalmitis following 
cataract surgery over the nine-year period between July 1, 
1995 and June 30, 2004 were reviewed. Institutional review 
board approval was obtained for this study. Patients included 
in the analysis presented within 30 days of cataract surgery 
with symptoms and signs consistent with endophthalmitis, 
including pain, blurred vision, anterior chamber reaction, 
hypopyon, and/or vitritis. Patients were excluded if there 
was a history of uveitis or retained lens material. All patients 
included in this analysis were followed for at least 30 days 
after initiation of endophthalmitis treatment.
Each patient was treated by a staff physician of the 
Kellogg Eye Center Retina Service with either one of 
two regimens according to EVS protocol: a vitreous tap 
and injection of intravitreal antibiotics, or vitrectomy and 
placement of intravitreal antibiotics. Antibiotic treatment 
consisted of vancomycin (1 mg/0.1 mL) with either ceftazi-
dime (2.25 mg/0.1 mL) or amikacin (400 μg/0.1 mL). Some 
patients additionally received subconjunctival, oral, and/or 
topical antibiotics, at the discretion of the treating physi-
cian. The treatment variable examined in this study was the 
injection of IVD. The decision to inject IVD was based on 
treating physician preference. Two physicians used adjunc-
tive IVD routinely, two never used adjunctive IVD, and two 
based the decision on “clinical severity” as determined by the 
physician at the time the patient was examined (with more 
“severe” cases receiving IVD). Assignment of the treating 
physician to the patient was determined according to a call 
schedule, and as such could be considered random. Among 
the patients who received IVD, each had only one injection 
(400 μg/0.1 mL), which occurred at the time of the treatment 
intervention (tap and inject or vitrectomy). Some patients in 
each group (those treated with IVD and those without IVD) 
also received a subconjunctival injection of dexamethasone, 
some received oral prednisone, and some received topical 
steroids, also at the discretion of the treating physician.
Patients treated by vitrectomy had a vitreous biopsy 
analyzed by sending both initial undiluted and ﬁ  nal diluted 
vitreous washings for bacteriologic analysis. Patients not 
treated by vitrectomy underwent anterior chamber and vitre-
ous tap. Anterior chamber tap was performed by inserting 
a 30-gauge needle at the limbus with aspiration of 0.1 mL 
of aqueous. Vitreous tap was performed using a 25-gauge 
needle inserted through the pars plana with aspiration of 
0.1 mL of vitreous. All samples were immediately plated 
on culture media and sent to the Microbiology Laboratory 
at the University of Michigan for Gram stain, cultures, and 
determination of antibiotic sensitivities.
Each patient’s chart was reviewed to determine age, 
presenting visual acuity, interval between cataract surgery 
and diagnosis of endophthalmitis, anterior chamber reaction 
(graded on 1+ to 4 + scale), hypopyon (measured in millime-
ters), presence or absence of ﬁ  brin, endophthalmitis treatment 
regimen (vitrectomy or tap/injection), use of IVD, infecting 
organism, and post-treatment visual acuity and inﬂ  ammatory 
indices (cell/ﬂ  are, hypopyon, ﬁ  brin) at all available follow-up Clinical Ophthalmology 2008:2(1) 141
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visits. The primary outcome measures were visual acuity and 
the percentage of patients achieving a 3-line (or category) 
improvement in visual acuity. Visual acuity was measured 
using the Snellen acuity chart. If a patient was unable to read 
the Snellen chart, visual acuity was tested for the ability to 
count ﬁ  ngers, recognize hand motions, or detect light in a 
manner similar to that used in the EVS. All acuities were 
converted to a logMAR scale before statistical analyses were 
performed. If a patient was enucleated or eviscerated, they 
were assigned an acuity of “no light perception” (NLP) for 
purposes of analysis. Visual acuities at various intervals were 
compared using the Mann-Whitney U-test for comparing 
median values and the Pearson’s chi-square test for com-
paring proportions. Statistical signiﬁ  cance was assumed to 
have been reached when the chance of a type 1 error was less 
than 5%. Logistic regression was used to determine whether 
any of the factors listed above were associated with binary 
primary outcome measures. Repeated measures analysis 
was used to assess for differences in any of the inﬂ  amma-
tory measures as a function of time after treatment between 
the IVD and No-IVD groups. A mixed model regression 
analysis was used for the cell/ﬂ  are and hypopyon measures 
and a generalized estimating equation regression was used 
for the categorical index of presence or absence of ﬁ  brin. 
All three analyses adjusted for baseline differences between 
the two groups. SAS 9.1 statistical software (Cary, NC) was 
used for all analyses.
Results
Our series represents the largest of its kind to date, with 
64 patients meeting the inclusion criteria. Of these, 26 
(41%) were treated with IVD (IVD group) and 38 (59%) 
were treated without IVD (No-IVD group). The baseline 
characteristics were similar in both groups. The average 
age was 69.8 years in the IVD group and 73.2 years in the 
No-IVD group. The average interval between cataract sur-
gery and diagnosis of endophthalmitis was 7.4 days in the 
IVD group and 7.0 days in the No-IVD group. Intraocular 
inﬂ  ammatory scores (including grading of anterior chamber 
reaction, presence and height of hypopyon, and presence of 
ﬁ  brin in the anterior chamber) were similar in each group 
at presentation. A higher (but not statistically signiﬁ  cant) 
percentage of patients in the IVD group were treated with 
vitrectomy than in the No-IVD group (31% [8/26]) vs 16% 
[6/38] respectively, p = 0.15). In the IVD group, follow-up 
ranged from 30 days to 12 months with a mean of 110 days. 
In the No-IVD group, follow-up ranged from 30 days to 
24 months with a mean of 121 days.
The distribution of presenting visual acuities for the two 
groups is shown in Figure 1. Median baseline visual acuity 
was 3.0 logMAR (HM) in each group. Though the median 
presenting acuity was equal in the two groups, only 62% 
(16/26) of patients presented with visual acuity of Hand 
Motion or better in the IVD group versus 84% (32/38) in 
the No-IVD group (p = 0.04). The use of extravitreal (ie, 
oral, subconjunctival, and topical) steroids and antibiotics 
was similar in each group (data not shown).
A speciﬁ  c bacterium was identiﬁ  ed in 73% (19/26) of 
cases in the IVD group and 66% (25/38) of cases in the 
No-IVD group (Table 1). In the IVD group, organisms 
included coagulase-negative Staphylococcus (n = 12), Staph-
ylococcus aureus (n = 1), and Streptococcus species (n = 6). 
In the No-IVD group, organisms included coagulase-negative 
Staphylococcus (n = 14), S, aureus (n = 5), Streptococcus 
species (n = 2), Enterococcus (n = 1), and other (n = 3). In 
some instances, the organism was identiﬁ  ed with a non-
speciﬁ  c notation (eg, “Staphylococcus” or “Gram-poistive 
cocci”) or there was no documentation of the culture result 
(categorized as “not identiﬁ  ed” in Table 1).
The distribution of visual acuities at last follow-up in each 
group is displayed in Figure 2. The median visual acuities at 
last follow-up were similar at 20/40 in the IVD group and 
20/50 in the No-IVD group (p = 0.75). The percentage of 
patients with a 3-line improvement in visual acuity were 
also similar at 73.1% (19/26) in the IVD group and 81.6% 
(31/38) in the No-IVD group (p = 0.42). Twenty patients in 
the IVD group (76.9%) had a visual acuity of 20/400 or better 
at last follow-up compared with 31 (81.6%) in the No-IVD 
group (p = 0.65). Loss of vision after treatment was observed 
in only three patients in the IVD group and two patients in 
the No-IVD group.
Because there was a disparity in the distribution of pre-
senting visual acuities between the two groups, we compared 
visual acuity outcomes between the IVD and No-IVD groups 
at each presenting visual acuity (Table 2). The data conﬁ  rm 
the trend toward similar outcomes across presenting visual 
acuities, with the No-IVD group perhaps doing slightly better 
for most subgroups, but the numbers within each category 
were too small to allow for meaningful statistical analysis.
To help reduce possible confounding effects caused 
by differences in the virulence of various infecting strains, 
we performed a subgroup analysis including only patients 
infected with coagulase-negative Staphylococcus. The 
median presenting visual acuity for patients infected with 
coagulase-negative Staphylococcus was similar between the 
two groups at between CF and HM (p = 0.40). The median Clinical Ophthalmology 2008:2(1) 142
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ﬁ  nal visual acuity was 20/40 in the IVD group (n = 12) 
and 20/50 in the No-IVD group (n = 14). At last recorded 
follow-up for this subgroup, 3-line improvement in visual 
acuity was observed in 92% (11/12) of patients in the IVD 
group and 100% (14/14) in the No-IVD group.
Possible predictive factors for an improved visual outcome 
(3-line improvement at last follow-up) were evaluated 
individually using logistic regression. An intravitreal 
injection of dexamethasone (p = 0.59) was not among them. 
Other factors that were not signiﬁ  cantly associated with an 
improved visual outcome included a poor presenting visual 
acuity 20/400 (p = 0.55), vitrectomy (p = 0.23), and age 
(p = 0.15). Patients whose endophthalmitis was associated 
with coagulase-negative Staphylococcus as the causative agent 
were signiﬁ  cantly more likely to show an improved visual 
outcome (OR = 19.1; 95% CI = 2.3 to 160.1; p = 0.0065). 
Of the 26 patients whose endophthalmitis was attributed to 
coagulase-negative Staphylococcus, 25 (96%) had improved 
visual outcomes, whereas of the 30 patients who had other 
bacterial causes or no organism isolated, 17 (57%) showed 
improved visual outcomes (eight patients were not included 
because culture results either could not be determined or were 
nonspeciﬁ  c). A multiple logistic regression model conﬁ  rmed 
that only coagulase-negative Staphylococcus was predictive 
of visual improvement (OR = 21.7; 95% CI = 2.2 to 209.1; p 
= 0.0078) upon adjustment for presenting visual acuity, use 
of IVD, vitrectomy, and age.
The use of adjunctive IVD did not contribute to a more 
rapid resolution of inﬂ  ammation in our patients (Table 3). 
The intraocular inﬂ  ammatory scores of anterior chamber 
reaction, height of hypopyon, and presence of ﬁ  brin remained 
Table 1 Distribution of organisms in patients treated with or 
without adjunctive intravitreal dexamethasone (IVD). The Strep-
tococcus group has been subcategorized by strains
  IVD group  No-IVD group
  N (%)  n (%)
Not identiﬁ  ed  2 (7)  3 (8)
Culture negative  5 (19)  10 (26)
Coag – Staphylococcus  12 (46)  14 (37)
Staphylococcus aureus  1 (4)  5 (13)
“Staphylococcus” 0  1  (3)
Streptococcus  6 (23)  2 (5)
 Intermedius 1  (4)  0
 Mitis 1  (4)  0
 Sanguis 1  (4)  0
 Salivarius 1  (4)  0
 Pneumoniae  1 (4)  2 (5)
  Group B Streptococcus 1  (4)  0
  “Gram + cocci” 0  2  (5)
 Enterococcus 0  1  (3)
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Figure 1 Distribution of presenting visual acuities in patients treated with or without intravitreal dexamethasone (IVD). The percentage of patients presenting with HM or 
better vision was signiﬁ  cantly higher in the No-IVD group (p = 0.04).Clinical Ophthalmology 2008:2(1) 143
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similar between the two groups at various time points up to 
30 days after initiation of treatment (p = 0.24, p = 0.16, and 
p = 0.61, respectively). To determine whether an overall 
lack of difference between groups may mask a short-term 
impact of IVD, we assessed the difference in each of the 
inﬂ  ammatory indices between day 0 (day of treatment) and 
day 7 (1 week after treatment). This analysis, too, failed to 
detect any signiﬁ  cant difference between the two groups.
Discussion
The data presented here represent the largest analysis to 
date examining the potential role of intravitreal dexametha-
sone as an adjunct to antibiotics in the treatment of acute, 
post-cataract endophthalmitis. We attempted to determine 
the effect of adjunctive IVD on visual acuity and on the 
clearance of intraocular inﬂ  ammation. In our population, 
the primary outcome measures of median visual acuity and a 
3-line improvement in visual acuity showed no signiﬁ  cant 
difference between patients treated with or without IVD. 
Furthermore, we did not detect any signiﬁ  cant improvement 
in intraocular inﬂ  ammation in IVD patients relative to the 
No-IVD patients. Though we did not see a worse outcome 
in the IVD patients, as was observed in the study of Shah 
and colleagues (2000), our data agree with theirs in that they 
do not support the use of intravitreal dexamethasone as a 
routine adjunct to antibiotics in the treatment of post-cataract 
endophthalmitis.
A major limitation of our analysis, as well as that of Shah 
and colleagues (2000), is the retrospective nature of the study. 
The two additional papers on adjunctive IVD, one by Das 
and colleagues (1999) and another by Gan and colleagues 
(2005a), evaluated outcomes with adjunctive IVD through 
prospective randomized trials. Comparing our results with 
theirs is complicated by the different study designs and treat-
ment protocols. Irrespective of these differences, however, 
their results also failed to demonstrate any conclusive beneﬁ  t 
from the use of adjunctive IVD.
Our study had several limitations that might have affected 
our ability to detect an improved outcome in patients 
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Figure 2 Distribution of visual acuities at last follow-up in patients treated with or without intravitreal dexamethasone (IVD).
Table 2 Median visual acuity at last follow-up when control-
ling for presenting visual acuities. Presenting visual acuities are 
displayed on the left. Final Median VA = median visual acuity at 
last follow-up
Presenting Va  IVD group  No-IVD group
 Final  median  VA  Final  median  VA
LP 20/125–20/160  20/50
HM 20/80–20/100  20/50
CF 20/40  20/63
20/400 20/40  20/25–20/30Clinical Ophthalmology 2008:2(1) 144
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Table 3 Inﬂ  ammation scores for patients treated with or without adjunctive intravitreal dexamethasone (IVD).  The time points are 
days after treatment (Day 0).  The p-value represents the probability that there was a difference between the two groups over time
  IVD group  No-IVD group
  Day 0  Day1  Day 7  Day 30  Day 0  Day 1  Day 7  Day 30  p-value
Mean cell/ﬂ   are  2.9 2.1  0.9 0.3 2.7  2.3  1.2  0.3  0.24
(scale of 1–4)                 
Hypopyon (mm)  0.5  0.8  0.2  0  0.5  0.5  0.02  0  0.16
Fibrin present (%)  66  62  17  0  61  60  12  9  0.61
receiving IVD. One limitation was the difference between 
the distribution of presenting visual acuities in the IVD and 
No-IVD groups. This may have been reﬂ  ective of an indi-
vidual physician’s preference for using IVD in certain subsets 
of eyes (eg, worse presenting visual acuity) (Figure 1). Only 
63% of our patients presented with visual acuity of HM or 
better in the IVD group compared with 87% in the No-IVD 
group, yet the median visual acuity at last follow-up and the 
ﬁ  nal distributions of visual acuities are nearly identical. This 
could suggest that the IVD was beneﬁ  cial, at least for patients 
with poorer baseline visions. However, neither the univariate 
nor multivariate analyses indicated that presenting visual 
acuity was predictive of response to adjunctive IVD.
Another limitation of the study is the variability in the use 
of topical, subconjunctival, and oral steroids and antibiotics. 
This type of limitation is inherent in retrospective analyses. 
We suspect that these adjunctive treatments have limited 
effect on visual outcomes when compared with intravitreal 
therapies.
Though a higher percentage of patients in our IVD group 
were treated with vitrectomy (reﬂ  ecting the difference in 
presenting visual acuities and therefore the recommenda-
tions from the EVS), this difference was not statistically 
signiﬁ  cant. Patients treated with vitrectomy might have 
been expected to have more rapid improvement in visual 
acuity because of the removal of vitreous debris, but we 
found no association between vitrectomy and visual acu-
ity outcomes. We were also unable to detect a difference 
between the two groups in the rate of clearing of intraocular 
inﬂ  ammation based on anterior chamber reaction scores, 
hypopyon height, and presence of ﬁ  brin in the anterior 
chamber.
One factor that may have affected our results was the 
distribution of infecting organisms. There was a slightly 
higher rate of streptococcal infection (which might be more 
virulent) in the group treated with IVD and a higher rate of 
negative cultures in the No-IVD group. The relatively small 
numbers preclude statistical subgroup comparison. Patients 
infected with coagulase-negative Staphylococcus responded 
similarly in each group. The ﬁ  nding that patients infected 
with coagulase-negative Staphylococcus were signiﬁ  cantly 
more likely to have a 3-line improvement in visual acuity 
is in agreement with results from the EVS (Johnson et al 
1997), and is likely reﬂ  ective of the less virulent nature of 
this organism.
Our study is also limited by the lack of long-term follow-
up data regarding other secondary outcomes such as epiretinal 
membrane formation or need for vitrectomy to clear vitreous 
debris. The Retina Service at Kellogg Eye Center services a 
large geographic area, and patients often are returned to the 
care of the referring ophthalmologist when they appeared to 
be clinically stable and improving. Inspection of the limited 
data available at longer follow-up intervals revealed no 
substantial differences in visual acuity between the groups 
(data not shown).
Although Peyman and colleagues (1974) published the 
ﬁ  rst report of the use of IVD in the treatment of endophthal-
mitis more than 30 years ago, there is still no consensus 
regarding the use of IVD in the treatment of endophthalmitis. 
Our data and those from other investigators show that IVD 
seems to have minimal if any signiﬁ  cant effect on visual 
outcomes, and as such its routine use as an adjunct to intra-
vitreal antibiotics does not appear warranted. A randomized 
clinical trial to test the beneﬁ  t of adjunctive IVD would 
seem impractical, given the large number of patients that 
one would need to recruit to detect any signiﬁ  cant effect. 
More research is necessary to identify the speciﬁ  c virulence 
and inﬂ  ammatory mediators responsible for the damage to 
ocular structures in endophthalmitis as limiting such tissue 
destruction may not be achievable with adjunctive intravitreal 
steroids alone (Ermis et al 2007). Such work would help 
in the design of targeted adjunctive therapies speciﬁ  cally 
designed to minimize the collateral damage caused by the 
infection, and improve visual outcomes.
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